Company Description
XWELL, Inc. provides health and wellness services to travelers in the United States and internationally.
It operates in four segments: XpresSpa, XpresTest, Naples Wax Center, and Treat. The XpresSpa segment provides traveler’s spa services, including massage, and nail and skin care services, as well as spa and travel products.
The XpresTest segment offers diagnostic COVID-19 tests to airport employees and traveling public at XpresCheck Wellness Centers in airports; operates the CDC’s bio-surveillance program; and provides marketing support through HyperPointe business to various health and health-related channels.
The Napple Wax Center segment offers skincare and cometic products, as well as face and body waxing services.
The Treat segment provides access to wellness services for travelers at on-site centers. The company offers its services through stores and kiosks, as well as online.
The company was formerly known as XpresSpa Group, Inc. and changed its name to XWELL, Inc. in October 2022.
XWELL, Inc. is based in New York, New York.
| Country | United States |
| Founded | 2006 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 312 |
| CEO | Ezra Ernst |
Contact Details
Address: 254 West 31st Street, 11th Floor New York, New York 10001 United States | |
| Phone | 212 750 9595 |
| Website | xwell.com |
Stock Details
| Ticker Symbol | XWEL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001410428 |
| CUSIP Number | 98420U802 |
| ISIN Number | US98420U8027 |
| SIC Code | 7200 |
Key Executives
| Name | Position |
|---|---|
| Ezra T. Ernst | President, Chief Executive Officer and Director |
| Thomas Ian Brown | Chief Financial Officer |
| Patti Ward | Vice President of Biosecurity and Technology |
| Cara Soffer | General Counsel |
| Mike Heronime | Marketing Director |
| Peter Vermeulen | Head of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 11, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Aug 8, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Aug 8, 2025 | ARS | Filing |
| Aug 8, 2025 | DEF 14A | Other definitive proxy statements |
| Aug 7, 2025 | 8-K | Current Report |
| Jul 29, 2025 | PRE 14A | Other preliminary proxy statements |
| Jul 25, 2025 | 8-K | Current Report |
| Jul 3, 2025 | 424B3 | Prospectus |
| Jun 30, 2025 | EFFECT | Notice of Effectiveness |
| Jun 20, 2025 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |